Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2004 by Shahid Beheshti Medical University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Shahid Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT00370201
First received: August 30, 2006
Last updated: October 6, 2006
Last verified: March 2004
  Purpose

This clinical trial will test the efficacy and safety of oral colchicine in prevention of proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment


Condition Intervention Phase
Rhegmatogenous Retinal Detachment
Drug: colchicine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Shahid Beheshti Medical University:

Primary Outcome Measures:
  • proliferative vitreoretinopathy
  • retinal reattachment rate

Secondary Outcome Measures:
  • visual acuity
  • reoperation
  • macular pucker

Study Start Date: March 2004
Estimated Study Completion Date: August 2006
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Rhegmatogenous retinal detachment

Exclusion Criteria:

  • PVR grade C
  • Duration of retinal detachment ≥ one month
  • History of cataract surgery
  • History of RD surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00370201

Locations
Iran, Islamic Republic of
Hamid Ahmadieh,MD
Tehran, Iran, Islamic Republic of, 16666
Sponsors and Collaborators
Shahid Beheshti Medical University
Investigators
Principal Investigator: Hamid Ahmadieh, MD Ophthalmic Research Center of Shaheed Beheshti Medical University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00370201     History of Changes
Other Study ID Numbers: 8259
Study First Received: August 30, 2006
Last Updated: October 6, 2006
Health Authority: Iran: Ethics Committee

Keywords provided by Shahid Beheshti Medical University:
retinal detachment
proliferative vitreoretinopathy

Additional relevant MeSH terms:
Retinal Detachment
Vitreoretinopathy, Proliferative
Retinal Diseases
Eye Diseases
Colchicine
Gout Suppressants
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 30, 2014